Repligen Corp (RGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN)

RGEN 149.37

-4.5%

Jan 30 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Laz who wrote (366)	12/26/2007 12:31:25 PM
From: Harvey Allen	Read Replies (1) of 395

Generic I took from this post of Dr. Ron Garren's analysis back in November 2004 The current patent status allows each company to block the others use of CTLA4-Ig (a drug which has proven very effective in refractory rheumatoid arthritis patients in a recent Phase III trial). The whole post is here messages.finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next